论文部分内容阅读
目的:评估利妥希玛(Rituximab)治疗复发性晚期滤泡性淋巴瘤的临床疗效及不良反应。病人和方法:选择38例复发性晚期滤泡性淋巴瘤(Ⅰ期和Ⅱ期)或中心母细胞性/中心细胞性淋巴瘤病人,采用非随机多中心Ⅱ期实验方法进行研究;静脉滴注利妥希玛375mg/m2,每周1次,连用4次。结果:在可供评估的30例患者中,完全缓解(CR)5例,部分缓解(PR)9例,有2例呈轻微反应(MR),总反应率为47％。23例应用利妥希玛后未发生不良反应;13例因出现不良反应需减慢输入速度;2例因咽部水肿和过敏反应而停药。最常见的不良反应为发热(13例)和寒战(13例)。结论:在治疗复发性晚期滤泡性淋巴瘤时,利妥希玛呈现高抗淋巴瘤活性及中等治疗相关毒性。
Objective: To evaluate the clinical efficacy and side effects of Rituximab in the treatment of recurrent advanced follicular lymphoma. Patients and Methods: A total of 38 patients with recurrent advanced follicular lymphoma (stage I and II) or patients with centroblastic / central cell lymphoma were enrolled in this study. The study was conducted in a non-randomized multicentre phase II trial. Intravenous instillation Rituximab 375mg / m2, once a week, once every 4 times. Results: Of the 30 patients available for evaluation, 5 had complete remission (CR), 9 had partial remission (PR), 2 had a mild reaction (MR), and the overall response rate was 47%. There were no adverse reactions in 23 cases after the application of Rituximab; in 13 cases, the input speed was slowed down due to adverse reactions; 2 cases were stopped because of throat edema and anaphylaxis. The most common adverse reactions were fever (13 cases) and chills (13 cases). Conclusion: Rituximab showed high anti-lymphoma activity and moderate treatment-related toxicity in the treatment of recurrent advanced follicular lymphoma.